PPN21: MIGRAINE IN FRANCE IN 2000:THERAPEUTICAL DATA  by Lucas, C et al.
Abstracts 161
mented relapse, 3 additional for relapse requiring IV cor-
ticosteroids, and 7/hospitalization). Standard costs were
assigned as follows: m ($1000/cycle); IV corticosteroids
used to treat relapses ($1250/occurrence); antibiotics
used to treat infections ($300/occurrence); hospitaliza-
tions ($1850/day); physician visits ($100/occurrence);
wages ($160/day). RESULTS: A cost-minimization anal-
ysis was done and the cost per patient per year was found
to be as follows: m therapy (m  $4000, p  $0); IV cor-
ticosteroid therapy (m  $250, p  $750); antibiotic
therapy (m  $96, p  $39); hospitalization (m 
$1850, p  $3145); physician visits (m  $40, p 
$100); lost wages (m  $448, p  $989). The total an-
nual cost per patient was $6684 in the m group and
$5023 in the p group. The annual cost of m ($4000) was
substantially offset by a reduction in other costs associ-
ated with p for a total annual incremental m cost of
$1661. CONCLUSIONS: MS is a chronic, debilitating
disease associated with considerable costs. Pharmacoeco-
nomic analyses suggest that m compares favorably with
other disease-modifying therapies for MS. Additional
data will be presented using remaining direct and indirect
cost drivers. The results of cost-effectiveness analyses in-
corporating patient outcome measures will also be pre-
sented.
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OBJECTIVE: GRIM 200 is an epidemiology survey on
migraine that was performed in France in 2000, ten years
after the first one (GRIM). The goal of this study was to
estimate the evolution of epidemiological data since ten
years, and to assess the impact of triptans on the disease
management and social repercussions of migraine.
METHODS: The survey was carried out by I.S.L, a na-
tional institute, on a representative sample of 10,585 sub-
jects in France aged 15 years and older according to the
quota method. There were 2 successive home interviews.
Persons suffering from headache were selected during the
first interview, or screening. They were then contacted
for a second interview with a validated questionnaire for
diagnosis of migraine. This questionnaire was the same
used in 1989 with supplementary questions concerning
triptans. RESULTS: We found a 8.2% prevalence of cer-
tain migraines (1-1 and 1-2 IHS) and a 17.3% prevalence
of certain migraines and migraine disorder (1-7 IHS).
Only 5.65% of headache sufferers (n  1486) were
treated by triptans. Of the 5.65% of patients using trip-
tans, we found 4.23% were migraine sufferers, 0.2% had
tension-type headache and 1.2% had chronic daily head-
ache. We found that 2.96% of the general population
were chronic daily headache patients (n  152). Of these,
18 patients were triptans abusers (11.8%). CONCLU-
SION: This study confirmed that triptans use by migraine
patients is very low in France in general population.
Overuse of triptans seems to be low in comparison with
other drugs.
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